Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-27 | Ms. Hamill holds a bachelor’s degree in business administration from the University of Arizona. Our board believes that Ms. Hamill’s extensive experience in the biopharmaceutical industry and leadership skills provides her with the qualifications and skills to serve our board of directors. |
| 2021-04-26 | Ms. Hamill holds a bachelor’s degree in business administration from the University of Arizona. |
| 2022-04-29 | Laura J. Hamill has served as a member of our board of directors since September 2019. From August 2018 to July 2019, Ms. Hamill served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., a biotechnology company, where she was responsible for leading the company’s commercial operations. Prior to joining Gilead, Ms. Hamill held a number of U.S. and international executive positions of increasing responsibility at Amgen, Inc., a biopharmaceutical company, from July 2000 to July 2018, most recently as Senior Vice President, U.S. Commercial Operations. In addition, Ms. Hamill previously held a variety of roles in the biopharmaceutical industry, including positions at F. Hoffmann-La Roche Ltd., a biopharmaceutical company. Ms. Hamill serves on numerous boards of directors, including Pardes Biosciences, Inc. and Y-mAbs Therapeutics, Inc. In the last five years, Ms. Hamill previously served on the board of directors of Acceleron Pharma, Inc., a publicly traded company, until its acquisition in December 2021. Ms. Hamill holds a bachelor’s degree in business administration from the University of Arizona. |
| Filing Date | Source Excerpt |
|---|---|
| 2024-06-14 | Ms. Hamill brings over 35 years of commercial expertise in the biopharmaceutical industry, having held a variety of executive leadership positions in the United States and Internationally. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22